Exploring the progress and trends of immunotherapy for type 1 diabetes: A comprehensive bibliometric analysis spanning nearly two decades

IF 8 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity Reviews Pub Date : 2025-01-28 DOI:10.1111/obr.13888

Yixin Jiang, Zhou Xu, Yuting Wu, Xinglei Li, Jitao Ling, Yixuan Chen, Zicheng Zhu, Pingping Yang, Xiao Liu, Deju Zhang, Jianping Liu, Xiaoping Yin, Jing Zhang, Peng Yu

{"title":"Exploring the progress and trends of immunotherapy for type 1 diabetes: A comprehensive bibliometric analysis spanning nearly two decades","authors":"Yixin Jiang, Zhou Xu, Yuting Wu, Xinglei Li, Jitao Ling, Yixuan Chen, Zicheng Zhu, Pingping Yang, Xiao Liu, Deju Zhang, Jianping Liu, Xiaoping Yin, Jing Zhang, Peng Yu","doi":"10.1111/obr.13888","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Immunotherapy is a crucial treatment for type 1 diabetes (T1D), yet analyses focusing on research priorities and trends in this field are limited. Therefore, this study employs bibliometric methods to systematically explore the current research status of immunotherapy for T1D.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Based on the Web of Science Core Collection Database, 1573 articles and review articles related to immunotherapy for T1D published from 2004 to 2023 were screened for bibliometric analysis. VOSviewer, CiteSpace, and R software were applied to comprehensively analyze the number of publications, journals, countries, authors, institutions, keywords, and references.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In the past two decades, the global annual publication rate has seen a significant increase of 238.24%. Almost 40% of all publications have appeared in the last 5 years, accounting for over 50% of total citations. Journals such as <i>Diabetes, Journal of Autoimmunity</i> and <i>Frontiers in Immunology</i> have exerted substantial influence. Collaboration across nations has been notably strong, with the United States leading the way. The University of Florida is the most productive institution. Terms like “nivolumab,” “ipilimumab,” “pembrolizumab,” and “immune checkpoint inhibitor(s)” gain considerable traction. The majority of research has clustered around themes such as immunomodulation, autoimmune diseases, immune checkpoint inhibitors, mesenchymal stem cells, and cell therapy. Precision medicine, immune checkpoint inhibitors, and nanotechnology are trending focal points in contemporary research.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The outcomes of the study are instrumental in enabling scholars to comprehend the evolving trajectory of immunotherapeutic approaches for T1D and facilitate the swift recognition of emerging research pathways.</p>\n </section>\n </div>","PeriodicalId":216,"journal":{"name":"Obesity Reviews","volume":"26 5","pages":""},"PeriodicalIF":8.0000,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/obr.13888","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Immunotherapy is a crucial treatment for type 1 diabetes (T1D), yet analyses focusing on research priorities and trends in this field are limited. Therefore, this study employs bibliometric methods to systematically explore the current research status of immunotherapy for T1D.

Methods

Based on the Web of Science Core Collection Database, 1573 articles and review articles related to immunotherapy for T1D published from 2004 to 2023 were screened for bibliometric analysis. VOSviewer, CiteSpace, and R software were applied to comprehensively analyze the number of publications, journals, countries, authors, institutions, keywords, and references.

Results

In the past two decades, the global annual publication rate has seen a significant increase of 238.24%. Almost 40% of all publications have appeared in the last 5 years, accounting for over 50% of total citations. Journals such as Diabetes, Journal of Autoimmunity and Frontiers in Immunology have exerted substantial influence. Collaboration across nations has been notably strong, with the United States leading the way. The University of Florida is the most productive institution. Terms like “nivolumab,” “ipilimumab,” “pembrolizumab,” and “immune checkpoint inhibitor(s)” gain considerable traction. The majority of research has clustered around themes such as immunomodulation, autoimmune diseases, immune checkpoint inhibitors, mesenchymal stem cells, and cell therapy. Precision medicine, immune checkpoint inhibitors, and nanotechnology are trending focal points in contemporary research.

Conclusion

The outcomes of the study are instrumental in enabling scholars to comprehend the evolving trajectory of immunotherapeutic approaches for T1D and facilitate the swift recognition of emerging research pathways.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity Reviews 医学-内分泌学与代谢

CiteScore

19.30

自引率

1.10%

发文量

130

审稿时长

1 months

期刊介绍： Obesity Reviews is a monthly journal publishing reviews on all disciplines related to obesity and its comorbidities. This includes basic and behavioral sciences, clinical treatment and outcomes, epidemiology, prevention and public health. The journal should, therefore, appeal to all professionals with an interest in obesity and its comorbidities. Review types may include systematic narrative reviews, quantitative meta-analyses and narrative reviews but all must offer new insights, critical or novel perspectives that will enhance the state of knowledge in the field. The editorial policy is to publish high quality peer-reviewed manuscripts that provide needed new insight into all aspects of obesity and its related comorbidities while minimizing the period between submission and publication.